CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
Rebalancing resources for healthcare and medicines: How much is enough?
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.
